All In Biotech

Drug Trial Radar · NCT03980821

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4635 in Japanese Patients With Advanced Solid Malignancies.

Last checked: Nov 19, 2026Latest source record: Dec 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jul 4, 2019

Primary completion

Sep 7, 2020

Study completion Sep 7, 2020

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of AZD4635 in Japanese patients with advanced solid malignancies. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in Cohort1 and 6 evaluable patients will be enrolled in Cohort2.

Conditions

  • Advanced Solid Malignancies

Interventions

  • AZD4635Drug

    AZD4635 taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Adverse event and SAETime frame: From the informed consent to 30 days post last dose
  2. The incidence of Dose-limiting toxicity (DLTs)Time frame: 25 days (Cycle0 and Cycle1)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.